Jacobi B. Hines

Hematology | Oncology

675 N St Clair St Ste 21-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC".

Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC".

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 08, 2024

Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report.

Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report.

Journal: JTO clinical and research reports

Published: June 10, 2024

A Response Letter by Cameron et al.

A Response Letter by Cameron et al.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 15, 2024

Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study.

Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study.

Journal: Cancers

Published: April 08, 2024

Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.

Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 13, 2023

Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.

Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 21, 2023

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: May 05, 2023

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

Journal: Therapeutic advances in medical oncology

Published: January 23, 2023

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Journal: Cancer discovery

Published: December 20, 2022

The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.

The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.

Journal: Current oncology reports

Published: November 07, 2022

Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.

Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.

Journal: Journal of medical case reports

Published: August 22, 2020

Hemodynamics in the cephalic arch of a brachiocephalic fistula.

Hemodynamics in the cephalic arch of a brachiocephalic fistula.

Journal: Medical engineering & physics

Published: August 15, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026